Breaking News
Close
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

As U.S. COVID-19 cases rise, so does demand for antivirals

Global May 17, 2022 18:24
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: Coronavirus disease (COVID-19) treatment pill Paxlovid is seen in a box, at Misericordia hospital in Grosseto, Italy, February 8, 2022. REUTERS/Jennifer Lorenzini/File Photo

By Ahmed Aboulenein

WASHINGTON (Reuters) -Rising COVID-19 cases are driving up the use of therapeutics, with Pfizer Inc (NYSE:PFE)'s oral antiviral treatment Paxlovid seeing a 315% jump over the past four weeks, U.S. health officials said on Tuesday.

The increase in U.S. cases and hospitalizations is starting to affect recommendations on behavior, with New York City, the nation's most populous city, advising stricter mask usage but stopping short of new mandates. Apple (NASDAQ:AAPL) has scrapped return to office plans.

"Increasingly, we'll see this virus hit people who are substantially older, frail, have underlying illnesses, or are distinctly immunocompromised," said Dr. William Schaffner, infectious disease expert at Vanderbilt University Medical Center in Nashville.

"But we now have better treatments and many of those people will leave the hospital vertically rather than horizontally."

The United States is averaging nearly 97,000 new cases a day, up from about 73,000 a week ago, according to a Reuters tally https://graphics.reuters.com/HEALTH-CORONAVIRUS/USA-TRENDS/dgkvlgkrkpb. Cases have been gradually rising since hitting a recent low of 30,000 new infections a day in late March.

The U.S. Centers for Disease Control and Prevention on Tuesday estimated that about half of infections last week were from the BA.2.12.1 sublineage of the Omicron variant, which has been on the rise since mid-April and is already the dominant strain along much of the East Coast.

"The other thing that's going on is that we're providing the opportunity for spread; we've taken off our masks, we're going back to group activities both in business and for recreation," said Schaffner.

"Going forward, we will have to figure out when is the impact of this virus sufficient such that we might have to start putting our masks back on and doing more social distancing. That sort of discussion is going on in New York right about now," he added.

New York City raised its COVID-19 alert level to high on Tuesday with its health department strongly advising wearing masks in all public indoor settings for everyone and in crowded outdoor settings for those older than 65 or at high risk.

NEW WAVE

Based on population, the U.S. Northeast has seen the greatest rise in new cases in the last seven days, led by Connecticut, Rhode Island and Massachusetts.

There are currently nearly 20,000 people hospitalized across the country, up from 16,500 last week, according to a Reuters tally. Hospitalizations have also been steadily rising from a recent low of 12,000 in mid-April.

Based on population, the states with the most hospitalizations are Maine, New York and Delaware.

Deaths, a lagging indicator, have held fairly steady at a daily average between of 300 to 500. COVID-19 has killed more than a million U.S. residents since the start of the pandemic.

Nearly 115,000 courses of Paxlovid were dispensed during the first week of May, the Department of Health and Human Services said on Tuesday.

A total of 668,954 courses were administered out of the available supply of 3.3 million, HHS data show.

Paxlovid is approved to keep high-risk individuals with COVID-19 from becoming seriously ill. It is meant to taken for five days beginning shortly after symptom onset.

Providers gave out 230,257 courses of molnupiravir, Merck & Co's rival oral antiviral developed along with Ridgeback Biotherapeutics. About 3.2 million molnupiravir courses are available, HHS data show.

VACCINES, TESTS AND TREATMENTS

The White House said last month it was aiming to address unexpectedly light demand by expanding access to treatments like Paxlovid by doubling the number of locations at which they are available.

"In recent weeks we've gone from 20,000 sites with Paxlovid to approximately 35,000 and we'll keep working to increase availability," the senior health official said, adding that 88% of the population lived within 5 miles (8 km) of a site.

Health officials face a challenge in convincing the public that repeat vaccinations are beneficial, said Schaffner.

"We'll have to keep vaccinating because it would appear that to one degree or another over a period of months protection against serious disease begins to wane," he said.

The U.S. Food and Drug Administration on Tuesday authorized the use of a booster shot of Pfizer and BioNTech's vaccine for children aged 5 to 11, making everyone 5 or older eligible for a third shot.

The government has shipped around 360 million coronavirus tests to homes nationwide, the official said, and has opened a third round of ordering on its COVIDtest.gov website on Monday to allow additional requests.

As U.S. COVID-19 cases rise, so does demand for antivirals
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Our Apps
DOWNLOAD APPApp store
Investing.com
© 2007-2022 Fusion Media Limited. All Rights Reserved.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
  • Sign up for FREE and get:
  • Real-Time Alerts
  • Advanced Portfolio Features
  • Personalized Charts
  • Fully-Synced App
Continue with Google
or
Sign up with Email